Mark Espeland to Estrogen Replacement Therapy
This is a "connection" page, showing publications Mark Espeland has written about Estrogen Replacement Therapy.
Connection Strength
2.731
-
Espeland MA, Brinton RD, Hugenschmidt C, Manson JE, Craft S, Yaffe K, Weitlauf J, Vaughan L, Johnson KC, Padula CB, Jackson RD, Resnick SM. Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women. Diabetes Care. 2015 Dec; 38(12):2316-24.
Score: 0.483
-
Espeland MA, Brinton RD, Manson JE, Yaffe K, Hugenschmidt C, Vaughan L, Craft S, Edwards BJ, Casanova R, Masaki K, Resnick SM. Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes. Neurology. 2015 Sep 29; 85(13):1131-8.
Score: 0.474
-
Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, Vaughan L, Robinson J, Rapp SR, Goveas JS, Wactawski-Wende J, Stefanick ML, Li W, Resnick SM. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013 Aug 12; 173(15):1429-36.
Score: 0.415
-
Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004 Jun 23; 291(24):2959-68.
Score: 0.220
-
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017 09 12; 318(10):927-938.
Score: 0.138
-
Driscoll I, Shumaker SA, Snively BM, Margolis KL, Manson JE, Vitolins MZ, Rossom RC, Espeland MA. Relationships Between Caffeine Intake and Risk for Probable Dementia or Global Cognitive Impairment: The Women's Health Initiative Memory Study. J Gerontol A Biol Sci Med Sci. 2016 12; 71(12):1596-1602.
Score: 0.129
-
Coker LH, Espeland MA, Hogan PE, Resnick SM, Bryan RN, Robinson JG, Goveas JS, Davatzikos C, Kuller LH, Williamson JD, Bushnell CD, Shumaker SA. Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies. Neurology. 2014 Feb 04; 82(5):427-34.
Score: 0.107
-
Vaughan L, Espeland MA, Snively B, Shumaker SA, Rapp SR, Shupe J, Robinson JG, Sarto GE, Resnick SM. The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). Brain Res. 2013 Jun 13; 1514:3-11.
Score: 0.101
-
Goveas JS, Hogan PE, Kotchen JM, Smoller JW, Denburg NL, Manson JE, Tummala A, Mysiw WJ, Ockene JK, Woods NF, Espeland MA, Wassertheil-Smoller S. Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women's Health Initiative Memory Study. Int Psychogeriatr. 2012 Aug; 24(8):1252-64.
Score: 0.093
-
Goveas JS, Espeland MA, Hogan P, Dotson V, Tarima S, Coker LH, Ockene J, Brunner R, Woods NF, Wassertheil-Smoller S, Kotchen JM, Resnick S. Depressive symptoms, brain volumes and subclinical cerebrovascular disease in postmenopausal women: the Women's Health Initiative MRI Study. J Affect Disord. 2011 Jul; 132(1-2):275-84.
Score: 0.087
-
Espeland MA, Tindle HA, Bushnell CA, Jaramillo SA, Kuller LH, Margolis KL, Mysiw WJ, Maldjian JA, Melhem ER, Resnick SM. Brain volumes, cognitive impairment, and conjugated equine estrogens. J Gerontol A Biol Sci Med Sci. 2009 Dec; 64(12):1243-50.
Score: 0.079
-
Cann JA, Register TC, Adams MR, St Clair RW, Espeland MA, Williams JK. Timing of estrogen replacement influences atherosclerosis progression and plaque leukocyte populations in ApoE-/- mice. Atherosclerosis. 2008 Nov; 201(1):43-52.
Score: 0.071
-
Espeland MA, Coker LH, Wallace R, Rapp SR, Resnick SM, Limacher M, Powell LH, Messina CR. Association between alcohol intake and domain-specific cognitive function in older women. Neuroepidemiology. 2006; 27(1):1-12.
Score: 0.063
-
Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P, Ockene JK, Shumaker SA. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006 May; 91(5):1802-10.
Score: 0.062
-
Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin Trials. 2004; 1(5):440-50.
Score: 0.053
-
Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003 May 28; 289(20):2663-72.
Score: 0.051
-
Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med. 2002 Mar 25; 162(6):665-72.
Score: 0.047
-
Haring B, Liu J, Rapp SR, Shimbo D, Padula CB, Mozhui K, Li W, Espeland M, Wassertheil-Smoller S. Heart Rate, Brain Imaging Biomarkers and Cognitive Impairment in Older (=63 years) Women. Am J Cardiol. 2020 08 15; 129:102-108.
Score: 0.042
-
Jaramillo SA, Felton D, Andrews L, Desiderio L, Hallarn RK, Jackson SD, Coker LH, Robinson JG, Ockene JK, Espeland MA. Enrollment in a brain magnetic resonance study: results from the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI). Acad Radiol. 2007 May; 14(5):603-12.
Score: 0.017